0.7838  -0.14 (-15.16%)		01-23 16:00
Open: 0.87 High: 0.89 Volume: 139,245		Pre. Close: 0.9239 Low: 0.7701 Market Cap: 2(M)

Short term
Mid term
Targets	6-month :	1.42	1-year :	1.85
Resists	First :	1.21	Second :	1.59
Pivot price	0.83
Supports	First :	0.61	Second :	0.5
MAs	MA(5) :	0.95	MA(20) :	0.81
	MA(100) :	1.1	MA(250) :	1.71
MACD	MACD :	0	Signal :	-0.1
%K %D	K(14,3) :	25.6	D(3) :	33.6
RSI	RSI(14): 44.8
52-week	High :	5.46	Low :	0.61

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ PRFX ] has closed above bottom band by 39.1%. Bollinger Bands are 33% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	0.89 - 0.9	0.9 - 0.9
Low:	0.76 - 0.76	0.76 - 0.77
Close:	0.77 - 0.78	0.78 - 0.79

PainReform Ltd., a clinical stage specialty pharmaceutical company, engages in the development of therapeutics that provides an extended period of post-surgical pain relief in Israel. It engages in developing PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia. The company is currently conducting two Phase 3 clinical trials of PRF-110 for the treatment of patients undergoing bunionectomy surgery and hernia repair. PainReform Ltd. was incorporated in 2007 and is based in Tel Aviv, Israel.

Tue, 20 Jan 2026
PRF Technologies Files Its First Patent Application for - GlobeNewswire

Tue, 20 Jan 2026
Micro-climate forecasts from PRF aim to boost solar farm revenues - Stock Titan

Fri, 16 Jan 2026
PainReform's Corporate Name Changes To PRF Technologies To Reflect Expansion; Stock Up - Nasdaq

Thu, 15 Jan 2026
From pain drug to AI solar: PRF Technologies pivots into two big markets - Stock Titan

Mon, 12 Jan 2026
New drop-free eye drug implant shows early safety in cataract surgery - Stock Titan

Wed, 07 Jan 2026
PainReform Shareholders Approve All Proposals at Adjourned 2026 Annual Meeting - The Globe and Mail

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Underperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Underperform
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Outperform

Exchange: NASDAQ
Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Shares Out	4 (M)
Shares Float	2 (M)
Held by Insiders	4.8 (%)
Held by Institutions	1.5 (%)
Shares Short	67 (K)
Shares Short P.Month	146 (K)

EPS	29.89
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	4.19
Profit Margin	0 %
Operating Margin	0 %
Return on Assets (ttm)	-36.2 %
Return on Equity (ttm)	-127.7 %
Qtrly Rev. Growth	0 %
Gross Profit (p.s.)	0
Sales Per Share	0
EBITDA (p.s.)	-1.01
Qtrly Earnings Growth	0 %
Operating Cash Flow	-6 (M)
Levered Free Cash Flow	-5 (M)

PE Ratio	0.02
PEG Ratio	0
Price to Book value	0.18
Price to Sales	0
Price to Cash Flow	-0.52

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.